regulatory

News

EU warns of brain tumour risk with some contraceptives

EU pharmaceutical safety advisers have said that commonly used contraceptives may carry a small risk of a type of brain cancer with prolonged use.

News

Newron charts course forward for stalled schizophrenia drug

Newron thinks it may have reached an agreement with the FDA on a way to get the US development of its schizophrenia candidate evenamide back on track.

R&D

pharmaphorum podcast Episode 266, Parexel - Paul Bridges and Charlotte Moser

Parexel: Flawless execution, policy shifts & patient-centric...

Parexel's Paul Bridges & Charlotte Moser discuss Europe's biotech sector in the face of an innovation cliff.

News

Unicycive hits another hurdle with hyperphosphataemia drug

Unicycive Therapeutics' hopes of getting FDA approval of its drug for hyperphosphataemia in dialysis patients have been knocked back again.

News

Lilly, Regeneron among firms chosen for FDA fast plant pilot

Eli Lilly, Regeneron, and five other drugmakers will take part in an FDA pilot designed to make it quicker and easier to set up manufacturing plants.

R&D

Pharma manufacturing, bottles in a factory

BIOSECURE and beyond: What it really means for pharma supply...

The US pharmaceutical industry is entering a new phase of supply chain transformation.

EU warns of brain tumour risk with some contraceptives

Newron charts course forward for stalled schizophrenia drug

Parexel: Flawless execution, policy shifts & patient-centric...

Unicycive hits another hurdle with hyperphosphataemia drug

Lilly, Regeneron among firms chosen for FDA fast plant pilot

BIOSECURE and beyond: What it really means for pharma supply...

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

regulatory

Editor's Picks